Furthermore, the combination of anti-VEGF/VEGFR and PD-1/PD-L1 inhibitors has been granted FDA approval for the treatment of hepatocellular carcinoma and renal cell carcinoma [63–65]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.